Austin Px Pharmaceutics

Nov 13, 2024 | outsourcedpharma.com | Dave Miller |Austin Px Pharmaceutics |Louis Garguilo

By Dave Miller, Ph.D., AustinPx Pharmaceutics and Manufacturing AI tools and machine learning have prompted the drug discovery’s most recent paradigm shift, enabling researchers to build compounds in-silico, without the constraints  of the physical realm. Docking experiments establishing the binding efficiency of these novel molecules to the target site are also conducted in-silico.